Download this article

Camel-IDS appoints Thomas Ramdahl as Independent Director


  • The appointment follows the EUR 37m Series A round and supports the next growth stage
  • The Board now consists of Christina Takke (Chair), Karl Nägler, Mårten Steen, Morten Graugaard Døssing, Ohad Hammer, Jean-Louis Baudhuin, Thomas Ramdahl and Ruth Devenyns (CEO) 

Brussels (Belgium), 17 May 2019

Camel-IDS, a biotech company developing novel radiopharmaceuticals, today announced the appointment of Thomas Ramdahl, former Chief Executive Officer of Algeta, as an independent, non-executive director.

Dr Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and the first CEO of Algeta ASA (Algeta), a Norwegian biotech company that was successful in researching, developing and launching a radiopharmaceutical for prostate cancer. When Dr Ramdahl joined Algeta, he was one of six employees at the time, and he played an instrumental role in its success, serving in several senior positions within the company through to and post the acquisition of Algeta by Bayer AG in 2014 for US$2.9 Billion.

About Camel-IDS

Camel-IDS is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid single domain antibody fragments (sdAb) labeled with radioisotopes. The Company is advancing its lead product CAM-H2 towards a phase Ib/II trial targeting HER2-positive brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline. Breast cancer patients with tumors that overexpress HER2, a growth-promoting protein, can benefit from effective targeted treatments today, yet have a poor prognosis when the cancer progresses towards the brain. Camel-IDS’ lead program CAM-H2 aims to effectively irradiate brain lesions while sparing healthy tissue, based on its unique technology platform that leverages the favorable tissue distribution of camelid derived single domain antibodies linked to radionuclides. The company’s technology platform also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a high therapeutic dose for treatment.

Camel-IDS, a VUB spin-off company incorporated in 2014, secured EUR 37m in a Series A investment round in November 2018, led by V-Bio Ventures (Belgium) and Gimv (Belgium), joined by the co-lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel), BioMedPartners (Switzerland) and existing investors. For more information, please visit